About asciminib hydrochlo ride
BCR-ABL1 tyrosine kinase inhibitor
Used for
- Treats Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, including newly diagnosed adults.
- Treats adults previously treated with at least two tyrosine kinase inhibitors.
Usual adult dose
Usually 80 mg once daily or 40 mg twice daily; dosing depends on treatment history and prescription.
Common side effects
- Low blood platelets, white blood cells, or red blood cells
- Headache, tiredness, or muscle and joint pain
- Nausea, diarrhea, or abdominal pain
- Rash or increased pancreatic enzymes
Important warnings
- Can cause low blood counts, pancreatitis, and high blood pressure.
- Rarely, serious cardiovascular problems or abnormal heart rhythms may occur.
- Avoid food for two hours before and one hour after each dose.
- Do not stop or change treatment without the prescriber’s direction.
Pregnancy
May harm an unborn baby. Pregnancy testing and effective contraception are recommended during treatment and for one week after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for one week after the last dose.
Interactions
- Avoid strong CYP3A4 inhibitors and inducers; they can alter asciminib levels.
- Avoid sensitive CYP3A4 substrates when possible; their levels may rise.
- Avoid proton-pump inhibitors, which may reduce asciminib absorption.
- Asciminib can increase levels of certain statins and other medicines.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.